Evidence map›Paper›PMID 38190056›Full record

ArticleAnnals of surgical oncology2024

Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma.

Bogomir Milojevic, Aleksandar Janicic, Isidora Grozdic Milojevic, Nikola Grubor, Uros Bumbasirevic, Milan Radovanovic, Djordje Radisavcevic, Darko Jovanovic, Milan Sretenovic, Otas Durutovic and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Bogomir Milojevic *Clinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia. em2bogomir@yahoo.com.ORCID http://orcid.org/0000-0001-6784-8389
Aleksandar Janicic *Clinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia.
Isidora Grozdic MilojevicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Nikola GruborFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Uros BumbasirevicClinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia.
Milan RadovanovicClinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia.
Djordje RadisavcevicClinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia.
Darko JovanovicClinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia.
Milan SretenovicClinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia.
Otas DurutovicClinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia.
Sandra Sipetic GrujicicFaculty of Medicine, Institute of Epidemiology, University of Belgrade, Belgrade, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this work was to evaluate the prognostic potential of preoperative thrombocytosis for recurrence-free survival (RFS) and cancer-specific survival (CSS) among patients subjected to radical nephroureterectomy (RNU) due to UTUC. PATIENTS AND

methodsAnalytical cohort was composed of a single-center series of 405 patients treated between January 1999 and December 2020. Thrombocytosis was defined as a platelet count exceeding the threshold value of 400 × 10

resultsPreoperative thrombocytosis confirmed in 71 patients (17.5%) was significantly associated with the higher pathological tumor stage, lymph node metastasis, prior bladder cancer diagnosis, and preoperative anemia. With a median post-surgical follow-up period of 33.5 months, 125 patients (30.9%) experienced disease recurrence. The recurrence rate among patients with normal platelet levels was 13.6%, compared with 22.2% in those with preoperative thrombocytosis (p < 0.03). The 5-year RFS estimates reached 36.6% in the thrombocytosis-confirmed group. Multivariate analysis implied that preoperative thrombocytosis was a significant independent prognosticator of both poor RFS (HR 2.22, 95% CI 1.14-4.31, p = 0.02) and CSS (HR 2.48, 95% CI 1.14-3.09, p = 0.01).

conclusionsPatients with a clinically significant elevation of platelet count prior to RNU were more likely to have UTUC with advanced tumor stages and lymph node metastases. Preoperative thrombocytosis was an independent predictor of RFS and CSS in patients who underwent radical nephroureterectomy. Furthermore, preoperative thrombocytosis may complement and refine UTUC clinical prediction algorithms as an independent indicator of adverse survival outcomes.

Indexed as

Carcinoma, Transitional CellThrombocytosisUrinary Bladder NeoplasmsUrologic NeoplasmsHumansKaplan-Meier EstimateNeoplasm Recurrence, LocalPrognosisRetrospective StudiesRadical nephroureterectomyRecurrenceThrombocytosisUpper tract urothelial carcinoma

Identifiers

PMID38190056
OpenAlexW4390672251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.